Cargando…
Pembrolizumab for non‐small cell lung cancer with central nervous system metastases: A two‐case report
Non‐small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. Central nervous system metastases are a common complication of NSCLC and confer a poor prognosis and a dismal survival rate. Treatment is limited, has poor outcomes, and affects patient quality of life. Pembrolizumab is a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360200/ https://www.ncbi.nlm.nih.gov/pubmed/30614652 http://dx.doi.org/10.1111/1759-7714.12963 |